Short answer
RECURSION PHARMACEUTICALS, INC. (RXRX) filed an 8-K current report with the SEC on February 25, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q4 and full-year fiscal 2025 earnings released February 25, 2026.
RECURSION PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year fiscal 2025 earnings released February 25, 2026
- Full results in Exhibit 99.1: primary source for revenue, cash position, and pipeline spend details
Item 7.01 · Regulation FD Disclosure
- Recursion released an earnings presentation on Feb 25, 2026 in connection with its Q4/FY earnings call
- Full presentation details in Exhibit 99.2: key metrics and pipeline updates available there
- Company uses SEC filings, IR website, press releases, and social media as official investor communication channels
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RECURSION PHARMACEUTICALS, INC. 8-K filings
Get the next RXRX 8-K as it lands
Follow RXRX for push alerts, or ask the research agent what this filing means.